ICUIのチャート
ICUIの企業情報
| symbol | ICUI |
|---|---|
| 会社名 | ICU Medical Inc （ICUメディカル） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 医療機器_医療用品_ディストリビュ―タ― 医療関連（Health Care） |
| 概要 | 事業概要 ICUメディカル（ICU Medical Inc.）は、注入療法、腫瘍治療及び救命救急診療に使用される医療設備の開発・生産・販売に従事する。同社の製品ラインは針注入コネクタ、カスタム注入セット、有害薬物向けの閉鎖式薬物移送システム(CSTD)、高度なセンサーカテーテル、無針式閉鎖の採血システム、使い捨て可能な圧力変換器システム及び血行動態モニタリングシステムを含む。同社のクリティカルケア製品は血圧測定システム、SafeSet閉鎖の採血・保存システム、消耗品のTranspac血圧トランスデューサ及びその他のクリティカルケア製品を含む。主要な腫瘍学製品は、ChemoLock無針式CSTD、ChemoClave無針式CSTD及びDiana有害薬物複合システムを含む。 ICUメディカルは米国の医療機器メ―カ―。注入療法、抗がん剤療法および救命救急診療用に医療機器を開発、製造、販売する。患者の血流を確保する一方で、医療従事者への血液感染を防ぐことに焦点を当てる。主要製品は無針点滴コネクタ―、特殊点滴システム、カテ―テル・血流モニタリング・システム、有害薬物自動処理機などを含む。本社はカリフォルニア州。 icu medical is in the business of making connections -- human connections. we design and make some of the world's safest, most reliable medical devices and systems for infusion therapy, oncology, and critical care applications. our products improve patient outcomes by helping prevent bloodstream infections and protecting patients and healthcare workers from exposure to infectious diseases or hazardous drugs. our complete product line includes needlefree vascular access devices, custom infusion systems, closed delivery systems for hazardous drugs, advanced sensor catheters and hemodynamic monitoring systems. together, we help forge the human and emotional connections that are a vital link between patients and caregivers, that enhance clinical experience, and are the essence of outstanding quality-of-care. icu medical is headquartered in san clemente, california. |
| 本社所在地 | 951 Calle Amanecer San Clemente CA 92673 USA |
| 代表者氏名 | Vivek Jain ヴィーベック・ジャイン |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 949-366-2183 |
| 設立年月日 | 30682 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1992年 |
| 従業員数 | 703人 |
| url | www.icumed.com |
| nasdaq_url | https://www.nasdaq.com/symbol/icui |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 241.15800 |
| 終値（lastsale） | 267.83 |
| 時価総額（marketcap） | 5481818292.07 |
| 時価総額 | 時価総額（百万ドル） 5417.755 |
| 売上高 | 売上高（百万ドル） 1445.853 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 590.589 |
| 当期純利益 | 当期純利益（百万ドル） 88.84600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 ICU Medical Incorporated revenues increased 26% to $732.5M. Net income increased 91% to $35.9M. Revenues reflect United States segment increase of 29% to $556.4M. Net income benefited from Restructuring and strategic transaction decrease of 18% to $40.3M (expense) Change in fair value of contingent earn- decrease of 67% to $2M (expense). |
ICUIのテクニカル分析
ICUIのニュース
New York Life Investment Management LLC Increases Stock Holdings in ICU Medical, Inc. (NASDAQ:ICUI) 2023/06/05 10:37:49 The AM Reporter
New York Life Investment Management LLC increased its holdings in ICU Medical, Inc. (NASDAQ:ICUI – Get Rating) by 12.7% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 2,549 shares of the medical instruments supplier’s stock after purchasing an additional 288 shares during the quarter. New York Life Investment Management LLC’s holdings in […]
ICU Medical, Inc. 2023 Q1 - Results - Earnings Call Presentation 2023/05/09 05:14:16 Seeking Alpha
The following slide deck was published by ICU Medical, Inc.
ICU Medical, Inc. (ICUI) Q1 2023 Earnings Call Transcript 2023/05/09 05:13:07 Seeking Alpha
ICU Medical, Inc. (NASDAQ:NASDAQ:ICUI) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ETCompany ParticipantsJohn Mills - Managing Partner, ICR, Inc.Vivek Jain - Chairman and Chief…
ICU Medical GAAP EPS of -$0.41 misses by $0.18, revenue of $568.65M beats by $3.35M 2023/05/08 20:17:15 Seeking Alpha
ICU Medical press release (NASDAQ:ICUI): Q1 GAAP EPS of -$0.41 misses by $0.18.Revenue of $568.65M (+4.7% Y/Y) beats by $3.35M.
ICU Medical Announces First Quarter 2023 Results 2023/05/08 20:05:00 GlobeNewswire
SAN CLEMENTE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended March 31, 2023.
ICU Medical downgraded to market perform at Raymond James on negative macro environment 2022/11/08 14:53:02 Seeking Alpha
Raymond James has downgraded ICU Medical to market perform from outperform citing a challenging macro environment such as foreign exchange rates and supply chain-related cost pressures.
ICU Medical, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:ICUI) 2022/11/08 07:56:27 Seeking Alpha
The following slide deck was published by ICU Medical, Inc.
ICU Medical, Inc. (ICUI) Q3 2022 Earnings Call Transcript 2022/11/08 05:42:06 Seeking Alpha
ICU Medical, Inc. (NASDAQ:NASDAQ:ICUI) Q3 2022 Earnings Conference Call November 07, 2022, 17:00 ET Company Participants John Mills - ICR Vivek Jain - CEO & Chairman Brian Bonnell - CFO…
ICU Medical Announces Third Quarter 2022 Results 2022/11/07 21:05:00 GlobeNewswire
The Company Reaffirms 2022 Fiscal Year Guidance The Company Reaffirms 2022 Fiscal Year Guidance
ICU Medical Q3 2022 Earnings Preview (NASDAQ:ICUI) 2022/11/07 05:40:59 Seeking Alpha
ICU Medical (ICUI) is scheduled to announce Q3 earnings results on Monday, November 7th, after market close.The consensus EPS Estimate is $1.46 (-29.5% Y/Y) and the consensus…
IV Bags Market is Likely to Rise at a CAGR of 5.8% from 2020 - 2032, TMR Study 2022/10/13 08:33:00 Accesswire
WILMINGTON, DE / ACCESSWIRE / October 13, 2022 / Transparency Market Research Inc. - IV bags are a key product segment in the field of parenteral packaging and are assisting in supplying plastic materials, needed for intravenous therapy at healthcare infrastructure units such as hospitals and clinics. Key factors behind the increasing demand for IV bags in parenteral packaging are ease of product availability and cost-effective nature. Prominent IV bags market players are making huge investments in research and development undertakings such as establishing R&D centers that function to manufacture improved IV bags that would requirements of patients suffering from different diseases. IV bags have also displayed high efficiency in the accurate delivery of medication to blood veins through the transfusion process. With healthcare facilities becoming accessible in remote locations, IV bags could witness increased demand during the assessment period, which could help grow the market. New IV bags launch is helping leading players in generating large amounts of revenue and assisting the players in gaining an edge over competitors.
ICU Medical Announces Time of Third Quarter 2022 Earnings Conference Call 2022/10/06 12:30:00 GlobeNewswire
SAN CLEMENTE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2022 earnings release and conference call.
Closed-System Transfer Devices (CSTD) Market to Witness Huge Growth by Key Players: Becton Dickinson, Hospira, ICU Medical, Equashield, Corvida Medical 2022/09/26 09:57:12 OpenPR
The Closed-System Transfer Devices (CSTD) research report undoubtedly meets the strategic and specific needs of the businesses and companies. The report acts as a perfect window that provides an explanation of market classification, market definition, applications, market trends, and engagement.
ICU Medical to Participate at the Morgan Stanley 20th Annual Global Healthcare Conference 2022/09/08 12:30:00 GlobeNewswire
SAN CLEMENTE, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced that Company management will participate in a fireside chat at the Morgan Stanley Annual Global Healthcare Conference at 11:15 a.m. PT (2:15 p.m. ET) on Monday, September 12, 2022. Company management will also be participating in one-on-one meetings on Monday, September 12, 2022.
ICU Medical''s Return On Capital Employed Insights 2022/08/30 14:01:59 Benzinga
According to Benzinga Pro data, during Q2, ICU Medical (NASDAQ: ICUI ) posted sales of $561.00 million. Earnings were up 80.37%, but ICU Medical still reported an overall loss of $7.47 million. In Q1, ICU Medical brought in $543.12 million in sales but lost $38.07 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com